A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making
In clinical trials, when exploring multiple dose groups to establish efficacy and safety on one or more selected doses, adaptive designs with interim dose selection are often used for dropping less effective dose groups. When it takes a long time to observe primary outcomes, utilizing information on...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Contemporary Clinical Trials Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865420300466 |
id |
doaj-98cfd928fdc8427399861c140ef41492 |
---|---|
record_format |
Article |
spelling |
doaj-98cfd928fdc8427399861c140ef414922020-11-25T02:44:53ZengElsevierContemporary Clinical Trials Communications2451-86542020-06-0118100562A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-makingXiaotian Chen0Alan Hartford1Jun Zhao2Data and Statistical Sciences, AbbVie Inc, North Chicago, IL, United States; Corresponding author.Statistical and Quantitative Sciences, Takeda Pharmaceuticals Inc, Cambridge, MA, United StatesData Science, Astellas Pharma Global Development, Northbrook, IL, United StatesIn clinical trials, when exploring multiple dose groups to establish efficacy and safety on one or more selected doses, adaptive designs with interim dose selection are often used for dropping less effective dose groups. When it takes a long time to observe primary outcomes, utilizing information on a surrogate endpoint available at an earlier interim may be preferred for selecting which dose to continue. We propose a Bayesian model-based approach where historical data can be leveraged to incorporate a correlation model for investigating the design's operating characteristics. Simulation studies were conducted and the method can be readily applied for power and sample size calculations.http://www.sciencedirect.com/science/article/pii/S2451865420300466Adaptive designBayesian modelCombination testSurrogate markerSurvival analysisHistorical data |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xiaotian Chen Alan Hartford Jun Zhao |
spellingShingle |
Xiaotian Chen Alan Hartford Jun Zhao A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making Contemporary Clinical Trials Communications Adaptive design Bayesian model Combination test Surrogate marker Survival analysis Historical data |
author_facet |
Xiaotian Chen Alan Hartford Jun Zhao |
author_sort |
Xiaotian Chen |
title |
A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making |
title_short |
A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making |
title_full |
A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making |
title_fullStr |
A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making |
title_full_unstemmed |
A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making |
title_sort |
model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making |
publisher |
Elsevier |
series |
Contemporary Clinical Trials Communications |
issn |
2451-8654 |
publishDate |
2020-06-01 |
description |
In clinical trials, when exploring multiple dose groups to establish efficacy and safety on one or more selected doses, adaptive designs with interim dose selection are often used for dropping less effective dose groups. When it takes a long time to observe primary outcomes, utilizing information on a surrogate endpoint available at an earlier interim may be preferred for selecting which dose to continue. We propose a Bayesian model-based approach where historical data can be leveraged to incorporate a correlation model for investigating the design's operating characteristics. Simulation studies were conducted and the method can be readily applied for power and sample size calculations. |
topic |
Adaptive design Bayesian model Combination test Surrogate marker Survival analysis Historical data |
url |
http://www.sciencedirect.com/science/article/pii/S2451865420300466 |
work_keys_str_mv |
AT xiaotianchen amodelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking AT alanhartford amodelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking AT junzhao amodelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking AT xiaotianchen modelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking AT alanhartford modelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking AT junzhao modelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking |
_version_ |
1724765407384961024 |